StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 3.79 Million USD | -25.12% |
| 2021 | 5.06 Million USD | 22.07% |
| 2020 | 4.15 Million USD | 2893.29% |
| 2019 | 138.7 Thousand USD | -25.38% |
| 2018 | 185.87 Thousand USD | -54.85% |
| 2017 | 411.66 Thousand USD | -60.95% |
| 2016 | 1.05 Million USD | 223.54% |
| 2015 | 325.8 Thousand USD | -84.58% |
| 2014 | 2.11 Million USD | 1602.71% |
| 2013 | 124.07 Thousand USD | -55.93% |
| 2012 | 281.55 Thousand USD | 185.17% |
| 2011 | 98.73 Thousand USD | -48.97% |
| 2010 | 193.47 Thousand USD | -82.32% |
| 2009 | 1.09 Million USD | -6.34% |
| 2008 | 1.16 Million USD | -46.62% |
| 2007 | 2.18 Million USD | -22.29% |
| 2006 | 2.81 Million USD | -38.72% |
| 2005 | 4.59 Million USD | 148.15% |
| 2004 | 1.85 Million USD | -36.24% |
| 2003 | 2.9 Million USD | 1815.64% |
| 2002 | 151.64 Thousand USD | 23315931.11% |
| 2001 | 0.65 USD | -2.55% |
| 2000 | 0.67 USD | -100.0% |
| 1999 | 67.9 Thousand USD | 10430717.06% |
| 1998 | 0.65 USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 519.58 Thousand USD | 0.0% |
| 2024 Q2 | 390.08 Thousand USD | -24.92% |
| 2023 Q3 | 745.48 Thousand USD | -6.03% |
| 2023 Q1 | 778.51 Thousand USD | 15.08% |
| 2023 Q2 | 793.3 Thousand USD | 1.9% |
| 2022 Q1 | 1.32 Million USD | -12.07% |
| 2022 Q3 | 799.4 Thousand USD | -19.92% |
| 2022 Q2 | 998.2 Thousand USD | -24.44% |
| 2022 FY | 3.79 Million USD | -25.12% |
| 2022 Q4 | 676.48 Thousand USD | -15.38% |
| 2021 Q1 | 2.47 Million USD | -4.47% |
| 2021 Q3 | 684.32 Thousand USD | 69.08% |
| 2021 Q4 | 1.5 Million USD | 119.53% |
| 2021 Q2 | 404.72 Thousand USD | -83.66% |
| 2021 FY | 5.06 Million USD | 22.07% |
| 2020 Q3 | 1.46 Million USD | 1366.66% |
| 2020 Q4 | 2.59 Million USD | 77.09% |
| 2020 FY | 4.15 Million USD | 2893.29% |
| 2020 Q1 | 11.36 Thousand USD | -77.25% |
| 2020 Q2 | 99.82 Thousand USD | 778.16% |
| 2019 FY | 138.7 Thousand USD | -25.38% |
| 2019 Q1 | 53.18 Thousand USD | -23.99% |
| 2019 Q4 | 49.97 Thousand USD | 117.59% |
| 2019 Q3 | 22.96 Thousand USD | 82.58% |
| 2019 Q2 | 12.58 Thousand USD | -76.34% |
| 2018 Q4 | 69.97 Thousand USD | -28.76% |
| 2018 FY | 185.87 Thousand USD | -54.85% |
| 2018 Q1 | 4463.00 USD | -91.6% |
| 2018 Q2 | 13.22 Thousand USD | 196.21% |
| 2018 Q3 | 98.22 Thousand USD | 642.97% |
| 2017 Q1 | 190.75 Thousand USD | -33.23% |
| 2017 FY | 411.66 Thousand USD | -60.95% |
| 2017 Q3 | 54.29 Thousand USD | -52.17% |
| 2017 Q4 | 53.11 Thousand USD | -2.17% |
| 2017 Q2 | 113.51 Thousand USD | -40.49% |
| 2016 FY | 1.05 Million USD | 223.54% |
| 2016 Q1 | 129.96 Thousand USD | 0.0% |
| 2016 Q4 | 285.7 Thousand USD | 157.15% |
| 2016 Q3 | 111.1 Thousand USD | -78.93% |
| 2016 Q2 | 527.34 Thousand USD | 305.75% |
| 2015 Q1 | 623.72 Thousand USD | 14.83% |
| 2015 Q2 | 585.25 Thousand USD | -6.17% |
| 2015 Q3 | -903.77 Thousand USD | -254.42% |
| 2015 FY | 325.8 Thousand USD | -84.58% |
| 2015 Q4 | - USD | 100.0% |
| 2014 FY | 2.11 Million USD | 1602.71% |
| 2014 Q4 | 543.19 Thousand USD | -45.32% |
| 2014 Q3 | 993.42 Thousand USD | 140.28% |
| 2014 Q2 | 413.45 Thousand USD | 126.42% |
| 2014 Q1 | 182.6 Thousand USD | 477.38% |
| 2013 FY | 124.07 Thousand USD | -55.93% |
| 2013 Q4 | 31.62 Thousand USD | -11.83% |
| 2013 Q3 | 35.86 Thousand USD | 276.68% |
| 2013 Q2 | 9522.32 USD | -79.96% |
| 2013 Q1 | 47.51 Thousand USD | -17.44% |
| 2012 Q2 | 55.35 Thousand USD | 752.71% |
| 2012 Q4 | 57.55 Thousand USD | -64.08% |
| 2012 Q1 | 6491.87 USD | 50.07% |
| 2012 Q3 | 160.21 Thousand USD | 189.42% |
| 2012 FY | 281.55 Thousand USD | 185.17% |
| 2011 FY | 98.73 Thousand USD | -48.97% |
| 2011 Q1 | 45.45 Thousand USD | 385.66% |
| 2011 Q2 | 10.1 Thousand USD | -77.76% |
| 2011 Q3 | 183.07 Thousand USD | 1711.17% |
| 2011 Q4 | 4325.75 USD | -97.64% |
| 2010 Q3 | 161.38 Thousand USD | 793.3% |
| 2010 Q4 | 9359.06 USD | -94.2% |
| 2010 Q2 | 18.06 Thousand USD | 316.95% |
| 2010 Q1 | 4332.94 USD | -98.93% |
| 2010 FY | 193.47 Thousand USD | -82.32% |
| 2009 Q4 | 406.28 Thousand USD | 19.65% |
| 2009 Q2 | 97.54 Thousand USD | -52.48% |
| 2009 Q1 | 205.28 Thousand USD | -38.19% |
| 2009 Q3 | 339.56 Thousand USD | 248.12% |
| 2009 FY | 1.09 Million USD | -6.34% |
| 2008 Q4 | 332.09 Thousand USD | 16.2% |
| 2008 Q1 | 285.9 Thousand USD | -44.01% |
| 2008 Q2 | 283.39 Thousand USD | -0.88% |
| 2008 Q3 | 285.79 Thousand USD | 0.85% |
| 2008 FY | 1.16 Million USD | -46.62% |
| 2007 FY | 2.18 Million USD | -22.29% |
| 2007 Q1 | 1.44 Million USD | 206.77% |
| 2007 Q2 | 507.23 Thousand USD | -64.88% |
| 2007 Q3 | 190.53 Thousand USD | -62.44% |
| 2007 Q4 | 510.62 Thousand USD | 168.0% |
| 2006 Q4 | 470.82 Thousand USD | -40.14% |
| 2006 Q3 | 786.56 Thousand USD | 0.39% |
| 2006 Q2 | 783.53 Thousand USD | 5.21% |
| 2006 Q1 | 744.74 Thousand USD | -58.29% |
| 2006 FY | 2.81 Million USD | -38.72% |
| 2005 Q2 | 1.22 Million USD | 68.48% |
| 2005 Q3 | 766.68 Thousand USD | -37.32% |
| 2005 FY | 4.59 Million USD | 148.15% |
| 2005 Q4 | 1.78 Million USD | 132.91% |
| 2005 Q1 | 726 Thousand USD | -45.16% |
| 2004 FY | 1.85 Million USD | -36.24% |
| 2004 Q2 | 167.4 Thousand USD | 1.87% |
| 2004 Q4 | 1.32 Million USD | 632.12% |
| 2004 Q1 | 164.33 Thousand USD | -86.91% |
| 2004 Q3 | 180.81 Thousand USD | 8.01% |
| 2003 Q2 | 185.61 Thousand USD | -84.41% |
| 2003 Q3 | 172.86 Thousand USD | -6.87% |
| 2003 Q4 | 1.25 Million USD | 625.99% |
| 2003 Q1 | 1.19 Million USD | 1148.56% |
| 2003 FY | 2.9 Million USD | 1815.64% |
| 2002 FY | 151.64 Thousand USD | 23315931.11% |
| 2002 Q4 | 95.34 Thousand USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q1 | 0.65 USD | -0.08% |
| 2001 FY | 0.65 USD | -2.55% |
| 2001 Q4 | - USD | -100.0% |
| 2001 Q3 | 0.65 USD | 160622.14% |
| 2001 Q2 | - USD | -100.06% |
| 2000 Q4 | 0.65 USD | -4.07% |
| 2000 Q3 | 0.68 USD | 0.0% |
| 2000 Q1 | 0.69 USD | -100.0% |
| 2000 FY | 0.67 USD | -100.0% |
| 1999 FY | 67.9 Thousand USD | 10430717.06% |
| 1999 Q4 | 67.9 Thousand USD | 10149235.37% |
| 1999 Q1 | 0.66 USD | 0.0% |
| 1999 Q3 | 0.67 USD | -1.34% |
| 1999 Q2 | 0.68 USD | 2.31% |
| 1998 FY | 0.65 USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -315.671% |
| Arrayit Corporation | 4.37 Million USD | 13.301% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 85.323% |
| Bioqual, Inc. | 58.59 Million USD | 93.523% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 75.189% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.949% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 40.387% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -260.889% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 90.563% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -748.064% |
| InVitro International | 792.62 Thousand USD | -378.797% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 65.905% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 47.467% |
| NovelStem International Corp. | 12 Thousand USD | -31525.633% |
| Optigenex Inc. | 465.97 Thousand USD | -714.446% |
| PharmChem, Inc. | 6.01 Million USD | 36.879% |
| Proteome Sciences plc | 6.4 Million USD | 40.708% |
| Response Genetics, Inc | 18.04 Million USD | 78.963% |
| Rennova Health, Inc. | 13.03 Million USD | 70.888% |
| RushNet, Inc. | 1.78 Million USD | -112.267% |
| ScreenPro Security Inc. | 1.91 Million USD | -98.269% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| Todos Medical Ltd. | 7.69 Million USD | 50.681% |